About Q-Line Biotech IPO

Q-Line Biotech Ltd., incorporated in 2010, operates in the diagnostics and healthcare segment, focusing on the development, manufacturing, and distribution of reagents, diagnostic kits, and medical equipment. The company caters to hospitals, diagnostic labs, and medical institutions across India, either directly or through its distribution network. 

Its product portfolio spans multiple diagnostic segments, including clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and rapid/POC testing solutions. In addition to reagents and consumables, the company also deals in in-vitro diagnostic (IVD) equipment and pathology devices. 

Q-Line has built in-house manufacturing capabilities with a strong focus on R&D, reverse engineering, and quality control. As of December 2025, it had an annual capacity of around 1.4 million diagnostic kits and 1,200 Selectra machines. Its operations are supported by a mix of in-house teams and third-party workforce to ensure scale and efficiency.

Q-Line Biotech IPO Subscription Breakdown

Investory CategorySubscription PercentageAmount Raised (₹ Crores)
Qualified Institutional Buyers (QIBs)50%22,36,000 crores
Non-Institutional Investors (NIIs)15%6,70,800 crores
Retail Individual Investors (RIIs)35%15,65,200 crores

Q-Line Biotech IPO Financial Highlights

No Data Found
No Data Found

Q-Line Biotech IPO Strengths & Weaknesses

  • Strong manufacturing and R&D capabilities with a focus on quality.

  • Diversified product portfolio across multiple diagnostic segments.

  • Pan-India distribution network with wide market reach.

  • Long-standing relationships with hospitals and diagnostic players.

  • Experienced promoters and management team.

Q-Line Biotech IPO Important Dates & Issue Details

Allotment DateListing DateRefund Date
26 May '26--27 May '26
Issue Composition:
Face Value10 per share
Total Issue Size44,72,000 shares (aggregating up to ₹2,74,400 crores)
Fresh Issue5,94,000 shares (aggregating up to ₹59,40,000 crores)
Offer for Sale0 shares of ₹10 (aggregating up to To be announced)
Issue TypeBook building
Post-Issue Shareholding Pattern:
Pre-Issue Shareholding96.77 shares
Post-Issue Shareholding0 shares

Q-Line Biotech IPO Lot Size and Investment Details

Minimum Lot Size--
Maximum Lot Size (Retail)--

The lot size of Q-Line Biotech ipo has been designed to ensure broad participation while maintaining optimal price discovery.

How to Apply for Q-Line Biotech IPO

  1. Log in to your Choice account
  2. Select IPO
  3. Enter the number of lots and your price
  4. Verify UPI ID
  5. Complete the transaction on your UPI app

Q-Line Biotech IPO Contact & Registrar Details

Contact Details

Address

Address

298-281 Transport Nagar Kanpur Road Adjacent Transport Nagar Lucknow

Phone Number

Phone Number

+91 0522 2435570

Registrar Details

Address

Registrar Name

Purva Sharegistry (India) Pvt.Ltd.

Optivalue Tek Consulting Ltd IPO Lead Manager(s)

Book Running Lead Manager(s)
Hem Securities Ltd | Share India Capital Services Pvt Ltd

Q-Line Biotech IPO FAQs

The minimum lot size is 400 shares with a price band of ₹326 to ₹343 per share, requiring a minimum investment of ₹2,74,400.

Check allotment status on the registrar's website using PAN number or application number after the Q-Line Biotech IPO allotment date.

The listing date of Q-Line Biotech IPO is scheduled for -- on NSE.

Investment decisions should be based on your risk appetite, financial goals, and a thorough analysis of the company's fundamentals and growth prospects.

Consider factors like company fundamentals, valuation, market conditions, and your investment portfolio before making any investment decision.

You can Q-Line Biotech IPO apply online through your broker's trading platform, mobile app, or through the ASBA facility via internet banking.

The Q-Line Biotech IPO allotment date and listing date are 26 May '26and --, respectively.

Yes, you can apply through your bank's internet banking portal. The funds will remain in your account until allotment, and no need for separate IPO funding.